Navigation Links
Small assist device used in emergency case as twin, heart booster pumps for first time in US
Date:11/12/2010

The Bluhm Cardiovascular Institute of Northwestern Memorial Hospital recently implanted a patient with two of the smallest experimental ventricular assist devices (VADs) currently available for study in humans. VADs are designed to assist either the right (RVAD) or left (LVAD) ventricle, or both (BiVAD) at once. This is the first time that two Heartware VADs have been implanted in the left and right ventricles anywhere in North Americaa "game changer" in the realm of heart assist devices according to Patrick M. McCarthy, MD, chief of the hospital's Division of Cardiac Surgery and director of the hospital's Bluhm Cardiovascular Institute.

"The world doesn't need the artificial heart anymore," said Dr. McCarthy, who is also the Heller-Sacks Professor of Surgery at Northwestern University Feinberg School of Medicine. "The goal is total support of the heart. This biventricular approach achieves that without cutting out the patient's own heart, which is what happens with artificial heart implants."

According to Edwin C. McGee, Jr. MD, surgical director for the Bluhm Institute's Heart Transplant and Assist Device program and the lead cardiac surgeon who performed the implant, when the patient, 44-year-old James Armstrong, was transferred to Northwestern Memorial just weeks ago, he was near death with an aggressive state of myocarditis. Myocarditis is a severe inflammation of the heart tissue thatin some rare casescan be fatal when unaddressed.

Only about a dozen times before in Europe had the twin implant of the small Heartware VAD been performed, and now the approach would be Armstrong's best chances for survival. The Heartware VAD is under trial in the U.S. as an LVAD. Mr. Armstrong did not qualify for the current trial and was able to have the device implanted under a process known as "emergency use". Emergency use is defined as the use of an investigational article with a human subject in a life-threatening situation. Although such uses are not yet approved by the U.S. Food and Drug Administration, they are allowed when there is no standard acceptable treatment available and there is not sufficient time to obtain approval from an Institutional Review Board.

"As we do for all of our patients, we wanted the very best for Jim," said McGee. "Standard BiVAD pumps sit outside of the body and are plagued by an extremely high complication and mortality rate."

McGee added that another reason to study this system is because the configuration leaves patients' hearts intact. This, he says, lends itself to the possibility that in some rare cases the heart may actually recover. "Naturally, that remains to be seenbut it's possible," he says. This probability is obliterated with artificial hearts because essential components of the natural heart are removed.

McGee adds that one of the greatest advantages to patients is that the pumps are contained (implanted) completely within the chest. There are two small controlling leads in the body that connect to a small monitor and power source outside the body that can be carried in two small shoulder pouches.

"Using this device in a biventricular support configuration may offer total heart support to more individuals with improved quality of life and hopefully fewer complications, than with the currently approved devices," added McGee.


'/>"/>

Contact: Kris Lathan
klathan@nmh.org
312-926-2963
Northwestern Memorial Hospital
Source:Eurekalert

Related medicine news :

1. Unexpectedly small effects of mutations in bacteria bring new perspectives
2. UCI non-small cell lung cancer study highlights advances in targeted drug therapy
3. Small particles show big promise in beating unpleasant odors
4. Small business success spotlighted by USDA at conference
5. American Chemical Society Webinar focuses on NSFs small business funding programs
6. Health Care Reform Helps Small Businesses Offer Coverage: Report
7. 16.6 million small business employees could benefit from ACA provisions starting this year
8. Babies Born Late May Face Small Cerebral Palsy Risk
9. Small Amounts of Dark Chocolate May Guard Against Heart Failure
10. Henry Ford Hospital study: Donor Risk Index does not impact outcomes on a small scale
11. Small increases in vaccine cost can cause large gaps in protection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... New York, NY (PRWEB) , ... December 07, ... ... measurable amounts of the drug in their bodies, a researcher at the Icahn ... the journal Pediatric Research. , The study found that when young children are ...
(Date:12/7/2016)... LAKE CITY, UTAH (PRWEB) , ... December 07, ... ... productivity, today announced the release of Smart Device Remote Control through a new ... management across all platforms and strengthens its mobile solutions to help businesses maximize ...
(Date:12/7/2016)... ... December 07, 2016 , ... EnghouseSystems ... purchase price of approximately $17.4 million (net of the cash acquired), subject ... $13.2 million. Headquartered in Barcelona, Spain, Presence is a leading provider of ...
(Date:12/7/2016)... , ... December 07, 2016 , ... It is vital ... is with useful, properly analyzed data. The team at Beckman Coulter has designed Kaluza, ... 'need for speed' and the need to operate in a GLP (Good Laboratory Practice) ...
(Date:12/7/2016)... ... December 07, 2016 , ... A quote from Dr. Edward Hallowell, ... on social media that offer a rare glimpse into the mind of those people ... New York Times bestselling author, has described people with ADHD as having “Ferrari engines ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... -- Global Cervical Dysplasia Market: Scope and Methodology ... market analyzes the current and future prospects of ... summary, including a market snapshot that provides overall ... research is a combination of primary and secondary ... research efforts along with information collected from telephonic ...
(Date:12/7/2016)... -- Research and Markets has announced the addition of ... Forecast to 2021" report to their offering. ... , , The immunohistochemistry ... at a CAGR of 7.3% during the forecast period of 2016 to ... and rapidly increasing geriatric population across the globe are the primary driving ...
(Date:12/7/2016)... , Dec. 7, 2016  Palatin Technologies, Inc. ... closed on a previously disclosed underwritten public offering ... Genuity acted as sole book-running manager, Roth Capital ... Markets acted as co-manager for the offering. ... million in net proceeds, allowing us to continue ...
Breaking Medicine Technology: